Focused On-demand Library for Palmitoyltransferase ZDHHC8

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Our library distinguishes itself through several key aspects:

  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.







Alternative names:

Zinc finger DHHC domain-containing protein 8; Zinc finger protein 378

Alternative UPACC:

Q9ULC8; Q2TGE9; Q6ICL1; Q6ZNF5; Q7Z6L9


Palmitoyltransferase ZDHHC8, also known as Zinc finger DHHC domain-containing protein 8 or Zinc finger protein 378, plays a crucial role in cellular processes through the palmitoylation of various protein substrates. This enzyme is instrumental in regulating the localization and function of the ABCA1 transporter in cholesterol and phospholipid efflux, stabilizing and localizing the D(2) dopamine receptor DRD2, and potentially influencing glutamatergic transmission. Additionally, it facilitates the biogenesis of the SARS-CoV-2 spike protein, enhancing viral fusion with target cells.

Therapeutic significance:

Understanding the role of Palmitoyltransferase ZDHHC8 could open doors to potential therapeutic strategies, particularly in managing viral infections like COVID-19 by targeting spike protein palmitoylation, and in neurological disorders through modulation of dopamine receptor functions.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.